Luminex Corporation | Complexity Simplified.

#soliloquy-container-14815{opacity:1}#soliloquy-container-14815 li > .soliloquy-caption{display:none}#soliloquy-container-14815 li:first-child > .soliloquy-caption{display:block} Advance your COVID-19 antibody research with the xMAP SARS-CoV-2 Multi-Antigen IgG Assay.

Advance your COVID-19 antibody research with the xMAP SARS-CoV-2 Multi-Antigen IgG Assay.

Find out how multiplex technology can help scale up serology screening.

Guava® easyCyte™ Systems–the first benchtop flow cytometers... now better than ever! Learn More

ARIES SARS-CoV-2 Assay & NxTAG CoV Extended Panel: Now Authorized by the FDA Under EUA.

Clinical

Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, including infectious disease testing, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.

Research

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP Technology. Click here to start the conversation now.

Learn More

Luminex Blog

The Versatility of Multiplex Antibody Titer Assays for COVID-19 and Beyond

The COVID-19 outbreak that began in Wuhan, China in December 2019 was marked by an increase in the number of cases showing pneumonia-like symptoms. It was not until about a month after the outbreak began that genomic analysis identified a novel coronavirus as the causative agent. With the emergence of new pathogen strains, genomic assays are not always able to detect new variants, and after an infection, may not be able to identify which pathogens were involved. However, with serological assays that pick up polyclonal antibody responses, the conservation of epitopes—even with new variants—make it possible to identify the different pathogens circulating in an epidemic.

Continue Reading >

Visit our blog >

Workflow for the ARIES® SARS-CoV-2 Assay (EUA)

ARIES® SARS CoV 2 Assay Workflow (EUA)

Clinical Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, including infectious disease testing, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.Read More Research Our xMAP® Technology and its flexibl

Designed for use on the ARIES® System, the ARIES® SARS-CoV- 2 Assay is a moderate-complexity, sample-to-answer test that enables targeted SARS-CoV-2 detection. ARIES® consolidates the assay steps into a single workflow and reduces turnaround time with STAT and random batch testing.

Watch more videos >